Proportion of high-risk childhood cancer survivors adherent on the last day of follow-up, by risk type (up to Feb. 28, 2020)*
| Characteristic | Survivors at risk of colorectal cancer (%) n = 327 | Survivors at risk of breast cancer (%) n = 234 | Survivors at risk of cardiomyopathy (%) n = 3205 |
|---|---|---|---|
| Overall | 12.8 | 6.4 | 52.7 |
| Age at first diagnosis, yr | |||
| 0–4 | 5.7 | 0 | 59.6 |
| 5–11 | 8.7 | 5.0 | 54.8 |
| 12–18 | 18.2 | 8.2 | 45.3 |
| Age at end of follow-up, yr | |||
| 18–24 | 0 | 7.5 | 72.5 |
| 25–29 | 5.4 | 6.0 | 54.0 |
| 30–34 | 17.4 | 4.3 | 42.0 |
| 35–39 | 21.3 | 9.7 | 37.8 |
| 40–44 | 21.1 | 0 | 29.9 |
| 45–49 | – | – | 16.9 |
| 50–54 | – | – | 0 |
| Sex | |||
| Female | 21.5 | 6.4 | 56.9 |
| Male | 7.1 | NA | 49.5 |
| Rurality and neighbourhood income, end of follow-up | |||
| Rural | 6.7 | 0 | 54.8 |
| Urban and income quintile 1 | 15.0 | 0 | 47.0 |
| Urban and income quintile 2 | 14.3 | 8.8 | 55.5 |
| Urban and income quintile 3 | 14.3 | 7.0 | 55.9 |
| Urban and income quintile 4 | 16.4 | 7.3 | 51.5 |
| Urban and income quintile 5 | 9.8 | 14.3 | 56.5 |
| Diagnosis | |||
| Leukemias | 10.0 | 4.0 | 57.9 |
| Lymphomas and neoplasms | 16.1 | 8.1 | 49.6 |
| Solid tumours and other categories | 10.7 | 3.3 | 47.5 |
| Period of diagnosis | |||
| 1986–1996 | 13.6 | 6.8 | 40.6 |
| 1997–2007 | 10.7 | 4.1 | 58.9 |
| 2008–2014 | – | 15.8 | 67.4 |
| Anthracycline dose | |||
| None | 8.1 | 5.1 | 38.4 |
| < 250 mg/m2 | 15.1 | 5.9 | 54.8 |
| ≥ 250 mg/m2 | 14.5 | 10.3 | 50.8 |
| Transplant | |||
| Allogenic | 12.0 | 5.6 | 49.2 |
| Autologous | 9.1 | 0 | 46.3 |
| None | 13.1 | 6.8 | 53.2 |
| Radiation | |||
| Breast and abdomen or pelvis | 13.3 | 6.6 | 39.9 |
| Breast only | 6.0 | 51.3 | |
| Abdomen or pelvis only | 11.1 | – | 57.3 |
| No radiation to any body region | – | – | 55.2 |
| ADG | |||
| None | 0 | 0 | 8.5 |
| Low, 1–5 | 9.5 | 4.2 | 54.5 |
| Intermediate, 6–9 | 15.3 | 8.0 | 62.0 |
| High, ≥ 10 | 28.8 | 9.2 | 67.9 |
| No. of primary care visits in the yr before end of follow-up | |||
| No visits | 1.9 | 3.5 | 35.2 |
| 1–3 | 17.2 | 3.7 | 59.0 |
| ≥ 4 | 18.5 | 10.6 | 60.2 |
| LTFU clinic visit in the yr before end of follow-up | |||
| No | 9.2 | 5.8 | 39.3 |
| Yes | 30.4 | 8.1 | 85.5 |
Note: – = no survivors in these categories, ADG = Aggregated Diagnosis Groups, LTFU = long-term follow-up.
↵* A lookback period before the last day of follow-up assessed whether the survivor was adherent. We calculated rates by taking the number of patients who were adherent on the last day of follow-up divided by the total number of eligible survivors.